Drugs / SA53-OS
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06578624 | Mar 2025 → Mar 2026 overdue | cancer | Lamassu Bio Inc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-04-11 | Lamassu Bio Inc | Regulatory POSSIBLE NEW HOPE FOR METASTATIC CANCER PATIENTS: FDA GRANTS APPROVAL FOR CLINICAL TRIALS OF LAMASSU’S GROUNDBREAKING CANCER TREATMENT PROTOCOL lamassubiotech.com ↗
Lamassu Biotech is proud to announce its pioneering effort to combat locally advanced metastatic p53 wild-type tumors has earned investigational new drug application (IND) approval from the Food and Drug Administration (FDA) to proceed in initiate Phase 1/2a clinical trials. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-04-11 | Lamassu Bio Inc | POSSIBLE NEW HOPE FOR METASTATIC CANCER PATIENTS: FDA GRANTS APPROVAL FOR CLINICAL TRIALS OF LAMASSU’S GROUNDBREAKING CANCER TREATMENT PROTOCOL lamassubiotech.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SA53-OS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06578624 ↗ |
| Action | Inhibit | “a novel MDM2 inhibitor” NCT06578624 ↗ |
| Route | Oral | “as an oral solution” NCT06578624 ↗ |
| Target | MDM2 | “a novel MDM2 inhibitor capable of selective activation of p53” NCT06578624 ↗ |